Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
Background
The
combined inhibition of BRAF and MEK is hypothesized to improve clinical
outcomes in patients with melanoma by preventing or delaying the onset
of resistance observed with BRAF inhibitors alone. This randomized phase
3 study evaluated the combination of the BRAF inhibitor vemurafenib and
the MEK inhibitor cobimetinib.
Methods
We randomly assigned 495 patients with previously untreated unresectable locally advanced or metastatic BRAF V600 mutation–positive melanoma to receive vemurafenib and cobimetinib (combination group) or vemurafenib and placebo (control group). The primary end point was investigator-assessed progression-free survival.Results
The median progression-free survival was 9.9 months in the combination group and 6.2 months in the control group (hazard ratio for death or disease progression, 0.51; 95% confidence interval [CI], 0.39 to 0.68; P<0.001). The rate of complete or partial response in the combination group was 68%, as compared with 45% in the control group (P<0.001), including rates of complete response of 10% in the combination group and 4% in the control group. Progression-free survival as assessed by independent review was similar to investigator-assessed progression-free survival. Interim analyses of overall survival showed 9-month survival rates of 81% (95% CI, 75 to 87) in the combination group and 73% (95% CI, 65 to 80) in the control group. Vemurafenib and cobimetinib was associated with a nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-drug discontinuation. The number of secondary cutaneous cancers decreased with the combination therapy.Conclusions
The
addition of cobimetinib to vemurafenib was associated with a
significant improvement in progression-free survival among patients with
BRAF V600–mutated metastatic melanoma, at the cost of some
increase in toxicity. (Funded by F. Hoffmann–La Roche/Genentech; coBRIM
ClinicalTrials.gov number, NCT01689519.)
No comments:
Post a Comment